Episodios
-
In this episode of Notes to Selfe, we dive into the fascinating world of women's health innovation with Sebastian Alexander, founder and CEO of VivoSensMedical. We explore the journey of OvulaRing, a groundbreaking technology transforming the way we understand and address female fertility and gynaecological diagnostics.
From the legacy of Sebastian's father-in-law, a pioneer in IVF and reproductive medicine, to the challenges of building a company in an underfunded and often overlooked sector, this episode is a deep dive into the realities of advancing women's health.
Together, we discuss:
* The unmet needs in women's reproductive health.
* How core body temperature is revolutionising fertility diagnostics.
* The gender data gap in healthcare and why it matters.
* The importance of patient capital in driving women's health innovation.
* How value-aligned investors can play a pivotal role in transforming the future of women's health.
If you are an investor, founder, or simply someone passionate about advancing healthcare for women, this episode will inspire and inform you.
----------
VivoSensMedical GmbH is a young, medical company from Leipzig that combines medical-scientific experience, technical know-how, marketing and sales expertise, and management practice. The company's vision is to transfer a wealth of experience of over 40 years of scientific work in clinical and user-friendly products to benefit both patients and doctors. VivoSensMedical strives to set new standards in diagnosis and treatment in the fields of gynaecology, reproductive and sexual medicine, and immunology and autoimmune diseases.
vivosensmedical.com
OvulaRing cycle tracker - determines your ovulation precisely
Get full access to Notes to Selfe at notestoselfe.substack.com/subscribe -
In this conversation, Maryann interviews Dr Hadas Ziso, CEO of Endocure, about the challenges of diagnosing endometriosis, a condition affecting 10% of women globally. Discover why endometriosis is the leading cause of infertility and where the future of women's health is headed in terms of diagnostics of this prevalent condition.
----
Dr Ziso is the driving force behind EndoCure, serving as its founder and CEO, where she channels her multidisciplinary expertise to revolutionise women's health. With an impressive academic background boasting four degrees, including BSc and MSc in biomedical engineering, a PhD in medical robotics, and an MBA, she brings a wealth of knowledge and insight to her leadership role.-----------
Endometriosis is a chronic condition impacting 10% of reproductive-age women, and EndoCure’s solution is an advanced system for the detection, mapping, and staging of lesions by robotic AI-powered ultrasound imaging. This solution represents a transformative leap forward in not only the diagnosis and management of endometriosis but also in surgical planning. It stands alone as the premiere solution offering a comprehensive lesion map to facilitate personalized treatment.
EndoCure Website
Get full access to Notes to Selfe at notestoselfe.substack.com/subscribe -
¿Faltan episodios?
-
Hormones rule our lives—from puberty to menopause, they influence everything from our mood to our health. But why do some women experience severe side effects while others don’t?
In this episode of the FemmeHealth Founder Series, I sit down with Dr. Paulina Cecula, co-founder of Dama Health, to:
📌 explore the groundbreaking science behind personalized hormone therapy.
📌 discuss the complex interplay of genetics, metabolism, and microbiome, and why trial-and-error contraception needs to become a thing of the past.
If you’re curious about the future of precision medicine in women’s health or simply want to understand your body better, this is an episode you can’t miss.
-------------------------
Dama Health with consortium partners Nura Health and Lasa Health, have recently been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s Health, to address critical unmet challenges in women’s health. Dama Health and its consortium partners will receive $3 million in funding over two years for early stage research efforts.
***Disclaimer***
All opinions are my own and personal. This is not investment advice. I do not provide any buying or selling recommendations, nor do I offer any investment advice. You are advised to conduct your own research and due diligence when making financial and investment decisions.
Get full access to Notes to Selfe at notestoselfe.substack.com/subscribe
